Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers

References

• Ambrose N, Morgan TA, Galloway J, et al. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25:1542–1550.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113–124.
   PubMed Web of Science ®Google Scholar
• Barr SG, Zonana-Nacach A, Magder LS, Petri M. Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1999;42:2682–2688.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Hughes GR. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009;18:869–874.
   PubMed Web of Science ®Google Scholar
• Györi N, Giannakou I, Chatzidionysiou K, Magder L, van Vollenhoven RF, Petri M. Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. Lupus Sci Med. 2017;4:e000192. doi:10.1136/lupus-2016-000192.
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev. 2012;11:593–595.
   PubMed Web of Science ®Google Scholar
• Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55:252–262. Epub 2015 Sep 5. doi:10.1093/rheumatology/kev311.
   PubMed Web of Science ®Google Scholar
• Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. Jan 27, 2017;pii: S0049-0172(17)30075–6. [ Epub ahead of print]. doi:10.1016/j.semarthrit.2017.01.010.
   PubMed Web of Science ®Google Scholar
• Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:1757–1762.
   PubMed Web of Science ®Google Scholar
• Arrico L, Abbouda A, Abicca I, Malagola R. Ocular complications in cutaneous lupus erythematosus: a systematic review with a meta-analysis of reported cases. J Ophthalmol. 2015;2015:254260.
   PubMedGoogle Scholar
• Papagiannuli E, Rhodes B, Wallace GR, Gordon C, Murray PI, Denniston AK. Systemic lupus erythematosus: an update for ophthalmologists. Surv Ophthalmol. 2016;61:65–82.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016;100:135–141.
   PubMed Web of Science ®Google Scholar
• Dammacco R. Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med. Dec 14, 2017. [ Epub ahead of print]. doi:10.1007/s10238-017-0479-9.
   Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–1277.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–2686.
   PubMed Web of Science ®Google Scholar
• Inês L, Silva C, Galindo M, et al. Rheumatic diseases registry of the Portuguese society of rheumatology. Registry of systemic lupus erythematosus patients of the Spanish society of rheumatology. Classification of systemic lupus erythematosus: systemic lupus international collaborating clinics versus American college of rheumatology criteria. A comparative study of 2,055 patients from a real-life, international systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2015;67:1180–1185.
   PubMed Web of Science ®Google Scholar
• Petri M, Kim MY, Kalunian KC, et al. OC-SELENA trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353:2550–2558.
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, et al. International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–530.
   PubMed Web of Science ®Google Scholar
• Dumas G, Prendki V, Haroche J, et al. Kikuchi-Fujimoto disease: retrospective study of 91 cases and review of the literature. Medicine (Baltimore). 2014;93:372–382.
   PubMed Web of Science ®Google Scholar
• das Chagas Medeiros MM, Bezerra MC, Braga FN, et al. Clinical and immunological aspects and outcome of a Brazilian cohort of 414 patients with systemiclupus erythematosus (SLE): comparison between childhood-onset, adult-onset, and late-onset SLE. Lupus. 2016;25:355–363.
   PubMed Web of Science ®Google Scholar
• Artim-Esen B, Çene E, Şahinkaya Y, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol. 2014;41:1304–1310.
   PubMed Web of Science ®Google Scholar
• Cozzani E, Drosera M, Gasparini G, Parodi A. Serology of lupus erythematosus: correlation between immunopathological features and clinical aspects. Autoimmune Dis. 2014;2014:321359.
   PubMedGoogle Scholar
• Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, et al. Closing the serological gap in the antiphospholipid syndrome: the value of “Non-criteria” antiphospholipid antibodies. J Rheumatol. Sep 1, 2017;44:1597–1602. [ Epub ahead of print]. doi:10.3899/jrheum.170044.
   PubMed Web of Science ®Google Scholar
• Jensen JL, Bergem HO, Gilboe IM, Husby G, Axéll T. Oral and ocular sicca symptoms and findings are prevalent in systemic lupus erythematosus. J Oral Pathol Med. 1999;28:317–322.
   PubMed Web of Science ®Google Scholar
• Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898.
   PubMedGoogle Scholar
• Shiboski CH, Shiboski SC, Seror R, et al. International Sjögren’s Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76:9–16.
   PubMed Web of Science ®Google Scholar
• Wang Y, Dou H, Liu G, et al. Hepatitis C virus infection and the risk of Sjögren or sicca syndrome: a meta-analysis. Microbiol Immunol. 2014;58:675–687.
   PubMed Web of Science ®Google Scholar
• Chung SH, Lim SA, Tchach H. Efficacy and safety of carbomer-based lipid-containing artificial tear formulations in patients with dry eye syndrome. Cornea. 2016;35:181–186.
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Mantelli F, Lambiase A, Mastropasqua A, Merlo D, Bonini S. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol. 2014;98:1016–1022.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Flamion B, Baudouin C. Keratitis in dry eye disease and topical ciclosporin A. Ocul Immunol Inflamm. 2017;1–10. [ Epub ahead of print]. doi:10.1080/09273948.2016.1276933.
   Web of Science ®Google Scholar
• Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;2:CD009327.
   PubMed Web of Science ®Google Scholar
• Sambursky R. Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. Clin Ophthalmol. 2016;10:2337–2343.
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48:3475–3486.
   PubMed Web of Science ®Google Scholar
• Borba HH, Funke A, Wiens A, Utiyama SR, Perlin CM, Pontarolo R. Update on biologic therapies for systemic lupus erythematosus. Curr Rheumatol Rep. 2016;18:44. doi:10.1007/s11926-016-0589-5.
   PubMed Web of Science ®Google Scholar
• Samy E, Wax S, Huard B, Hess H, Schneider P. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. Int Rev Immunol. 2017;36:3–19.
   PubMed Web of Science ®Google Scholar
• Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2017;69:1016–1027.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology (Oxford). 2015;54:2249–2256.
   PubMed Web of Science ®Google Scholar
• Frith P, Burge SM, Millard PR, Wojnarowska F. External ocular findings in lupus erythematosus: a clinical and immunopathological study. Br J Ophthalmol. 1990;74:163–167.
   PubMed Web of Science ®Google Scholar
• Shoughy SS, Jaroudi MO, Kozak I, Tabbara KF. Optical coherence tomography in the diagnosis of scleritis and episcleritis. Am J Ophthalmol. 2015;159:1045–1049.
   PubMed Web of Science ®Google Scholar
• Axmann S, Ebneter A, Zinkernagel MS. Imaging of the sclera in patients with scleritis and episcleritis using anterior segment optical coherence tomography. Ocul Immunol Inflamm. 2016;24:29–34.
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Uji A, Morooka S, Nishijima K, Yoshimura N. Morphological features in anterior scleral inflammation using swept-source optical coherence tomography with multiple B-scan averaging. Br J Ophthalmol. 2017;101:411–417.
   PubMed Web of Science ®Google Scholar
• Zur D, Neudorfer M, Shulman S, Rosenblatt A, Habot-Wilner Z. High-resolution ultrasound biomicroscopy as an adjunctive diagnostic tool for anterior scleral inflammatory disease. Acta Ophthalmol. 2016;94:e384–9.
   PubMed Web of Science ®Google Scholar
• Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum. 1988;31:1105–1110.
   PubMed Web of Science ®Google Scholar
• Au A, O’Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment. Clin Exp Ophthalmol. 2004;32:87–100.
   PubMed Web of Science ®Google Scholar
• Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006;15:3–12.
   PubMed Web of Science ®Google Scholar
• Preble JM, Silpa-Archa S, Foster CS. Ocular involvement in systemic lupus erythematosus. Curr Opin Ophthalmol. 2015;26:540–545.
   PubMed Web of Science ®Google Scholar
• Parchand SM, Vijitha VS, Misra DP. Combined central retinal artery and vein occlusion in lupus. BMJ Case Rep. 2017;2017:pii: bcr2016218848.
   Google Scholar
• Shoughy SS, Tabbara KF. Ocular findings in systemic lupus erythematosus. Saudi J Ophthalmol. 2016;30:117–121.
   PubMed Web of Science ®Google Scholar
• Wu C, Dai R, Dong F, Wang Q. Purtscher-like retinopathy in systemic lupus erythematosus. Am J Ophthalmol. 2014;158:1335–1341.
   PubMed Web of Science ®Google Scholar
• Kunavisarut P, Pathanapitoon K, Rothova A. Purtscher-like retinopathy associated with systemic lupus erythematosus. Ocul Immunol Inflamm. 2016;24:60–68.
   PubMed Web of Science ®Google Scholar
• Varma DD, Cugati S, Lee AW, Chen CS. A review of central retinal artery occlusion: clinical presentation and management. Eye (Lond). 2013;27:688–697.
   PubMed Web of Science ®Google Scholar
• Monov S, Hristova R, Dacheva R, et al. Acute necrotizing retinal vasculitis as onset of systemic lupus erythematosus: a case report. Medicine (Baltimore). 2017;96:e5754.
   PubMed Web of Science ®Google Scholar
• Zhu W, Wu Y, Xu M, et al. Antiphospholipid antibody and risk of retinal vein occlusion: a systematic review and meta-analysis. PLoS One. 2015;10:e0122814.
   PubMed Web of Science ®Google Scholar
• Karpik AG, Schwartz MM, Dickey LE, Streeten BW, Roberts JL. Ocular immune reactants in patients dying with systemic lupus erythematosus. Clin Immunol Immunopathol. 1985;35:295–312.
   PubMedGoogle Scholar
• Ahn SJ, Kim JM, Hong JH, et al. Efficacy and safety of intra-arterial thrombolysis in central retinal artery occlusion. Invest Ophthalmol Vis Sci. 2013;54:7746–7755.
   PubMed Web of Science ®Google Scholar
• Ahn SJ, Park KH, Ryoo NK, et al. No-reflow phenomenon in central retinal artery occlusion: incidence,risk factors, and clinical implications. PLoS One. 2015;10:e0142852.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Cho HY, Lee YJ, Lee BR, Shin JP. Intravitreal bevacizumab for severe vaso-occlusive retinopathy in systemic lupus erythematosus. Rheumatol Int. 2013;33:247–251.
   PubMed Web of Science ®Google Scholar
• Jeon S, Lee WK. Aggravated capillary non-perfusion after intravitreal bevacizumab for macular edema secondary to systemic lupus erythematosus and anti- phospholipid syndrome. Lupus. 2012;21:335–337.
   PubMed Web of Science ®Google Scholar
• Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol. 2008;86:925–927.
   PubMed Web of Science ®Google Scholar
• Talat L, Lightman S, Tomkins-Netzer O. Ischemic retinal vasculitis and its management. J Ophthalmol. 2014;2014:197675.
   PubMed Web of Science ®Google Scholar
• Kasturi S, Sammaritano LR. Corticosteroids in lupus. Rheum Dis Clin North Am. 2016;42:47–62.
   PubMed Web of Science ®Google Scholar
• Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. Lupus Sci Med. 2015;2:e000066.
   PubMed Web of Science ®Google Scholar
• Carli L, Tani C, Querci F, et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32:1071–1073.
   PubMed Web of Science ®Google Scholar
• Alderaan K, Sekicki V, Magder LS, Petri M. Risk factors for cataracts in systemic lupus erythematosus (SLE). Rheumatol Int. 2015;35:701–708.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017;16:411–419.
   PubMed Web of Science ®Google Scholar
• Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol. 2008;23:201–209.
   PubMedGoogle Scholar
• Payne JF, Hubbard GB 3rd, Aaberg TM Sr, Yan J. Clinical characteristics of hydroxychloroquine retinopathy. Br J Ophthalmol. 2011;95:245–250.
   PubMed Web of Science ®Google Scholar
• Latasiewicz M, Gourier H, Yusuf IH, Luqmani R, Sharma SM, Downes SM. Hydroxy-chloroquine retinopathy: an emerging problem. Eye (Lond). Feb 10, 2017;31:972–976. [ Epub ahead of print]. doi:10.1038/eye.2016.297.
   PubMed Web of Science ®Google Scholar
• Stelton CR, Connors DB, Walia SS, Walia HS. Hydrochloroquine retinopathy: characteristic presentation with review of screening. Clin Rheumatol. 2013;32:895–898.
   PubMed Web of Science ®Google Scholar
• Modi YS, Singh RP, Fine HF. Hydroxychloroquine: a brief review on screening, toxicity, and progression. Ophthalmic Surg Lasers Imaging Retina. 2016;47:207–217.
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxy-chloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–1394.
   PubMed Web of Science ®Google Scholar
• van der Tol L, Sminia ML, Hollak CE, Biegstraaten M. Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review. Br J Ophthalmol. 2016;100:3–8.
   PubMed Web of Science ®Google Scholar
• Chan TC, Jhanji V. Images in clinical medicine. Amiodarone-induced vortex keratopathy. N Engl J Med. 2015;372:1656.
   PubMed Web of Science ®Google Scholar
• Au A, Parikh V, Modi YS, Ehlers JP, Schachat AP, Singh RP. Hydroxychloroquine screening practice patterns within a large multispecialty ophthalmic practice. Am J Ophthalmol. 2015;160:561–8.e2.
   PubMed Web of Science ®Google Scholar
• Cukras C, Huynh N, Vitale S, Wong WT, Ferris FL 3rd, Sieving PA. Subjective and objective screening tests for hydroxychloroquine toxicity. Ophthalmology. 2015;122:356–366.
   PubMed Web of Science ®Google Scholar
• Marmor MF. Hydroxychloroquine screening alert: change is in the wind. Ophthalmic Surg Lasers Imaging Retina. 2017;48:96–98.
   PubMed Web of Science ®Google Scholar
• Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond). 2017;31:828–845.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44:902–906.
   PubMed Web of Science ®Google Scholar
• Bundhun PK, Kumari A, Huang F. Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e8086.
   PubMed Web of Science ®Google Scholar